JP2006508939A - 癌処置のための組成物 - Google Patents

癌処置のための組成物 Download PDF

Info

Publication number
JP2006508939A
JP2006508939A JP2004547934A JP2004547934A JP2006508939A JP 2006508939 A JP2006508939 A JP 2006508939A JP 2004547934 A JP2004547934 A JP 2004547934A JP 2004547934 A JP2004547934 A JP 2004547934A JP 2006508939 A JP2006508939 A JP 2006508939A
Authority
JP
Japan
Prior art keywords
glycogen
cell
agent
cells
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004547934A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006508939A5 (OSRAM
Inventor
ブルーノ ドイロン，
スコット ポウナル，
アンソニー チュン，
エリック シュー，
Original Assignee
エンジーン， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エンジーン， インコーポレイテッド filed Critical エンジーン， インコーポレイテッド
Publication of JP2006508939A publication Critical patent/JP2006508939A/ja
Publication of JP2006508939A5 publication Critical patent/JP2006508939A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03016—Phosphoprotein phosphatase (3.1.3.16), i.e. calcineurin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
JP2004547934A 2002-10-29 2003-10-29 癌処置のための組成物 Pending JP2006508939A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42236502P 2002-10-29 2002-10-29
PCT/IB2003/005562 WO2004039412A2 (en) 2002-10-29 2003-10-29 Compositions for cancer treatment

Publications (2)

Publication Number Publication Date
JP2006508939A true JP2006508939A (ja) 2006-03-16
JP2006508939A5 JP2006508939A5 (OSRAM) 2006-12-28

Family

ID=32230344

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004547934A Pending JP2006508939A (ja) 2002-10-29 2003-10-29 癌処置のための組成物

Country Status (7)

Country Link
US (2) US20050202559A1 (OSRAM)
EP (1) EP1556088A2 (OSRAM)
JP (1) JP2006508939A (OSRAM)
CN (1) CN1741821B (OSRAM)
AU (1) AU2003282306A1 (OSRAM)
CA (1) CA2503422A1 (OSRAM)
WO (1) WO2004039412A2 (OSRAM)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013504039A (ja) * 2009-09-02 2013-02-04 ナショナル・チン・フア・ユニバーシティ 致死性細胞を検出する方法および組成物ならびにその使用
JP2013135674A (ja) * 2013-01-11 2013-07-11 Tohoku Univ 運動に応答して筋肉細胞において発現変動するタンパク質及びそれらの受容体、それらをコードする遺伝子、並びにそれらを用いたスクリーニング方法
JP2015534946A (ja) * 2012-10-12 2015-12-07 ビジョン グローバル ホールディングス リミテッドＶｉｓｉｏｎ Ｇｌｏｂａｌ Ｈｏｌｄｉｎｇｓ Ｌｔｄ． がんの標的治療およびがんの再発予防のためのヘモグロビンベース系酸素運搬体含有医薬組成物

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381413B1 (en) * 1998-04-17 2008-06-03 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
WO2004111199A2 (en) * 2003-06-12 2004-12-23 University Of Colorado System Technology Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
US20070287718A1 (en) * 2003-11-06 2007-12-13 Green Simon R Methods for the Treatment of Multiple Myeloma Using Roscovitine
US7510710B2 (en) * 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
AU2005318836B2 (en) * 2004-12-21 2012-03-22 Viventia Bio Inc. Cancer specific antibody and cell surface proteins
EP1877060A2 (en) * 2005-04-28 2008-01-16 The Regents of the University of Colorado Therapeutic bifunctional compounds
JP2008543734A (ja) * 2005-05-02 2008-12-04 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド 脂肪酸代謝および解糖の阻害を提供する化合物の組み合わせ、または二官能性化合物を用いるヒトの炎症性および増殖性疾患を処置するためのシステムおよび方法
EP1917041A4 (en) * 2005-08-24 2010-09-29 Cedars Sinai Medical Center USE OF FRUCTOSE-BASED THERAPIES FOR CANCER TREATMENT
WO2007037533A1 (ja) * 2005-09-30 2007-04-05 Link Genomics, Inc. Ｐｐｐ１ｒ３ｄ遺伝子の治療的又は診断的用途
US20090011060A1 (en) * 2007-07-06 2009-01-08 Peter Koepke Campsiandra angustifolia extract and methods of extracting and using such extract
US7879369B2 (en) 2007-09-18 2011-02-01 Selvamedica, Llc Combretum laurifolium Mart. extract and methods of extracting and using such extract
US8394377B2 (en) * 2008-02-21 2013-03-12 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
EA018988B1 (ru) 2008-05-16 2013-12-30 Такеда Калифорния, Инк. Активаторы глюкокиназы
US9073985B2 (en) 2008-07-14 2015-07-07 The Regents Of The University Of Colorado, A Body Corporate Methods and products for treating proliferative diseases
WO2011009044A2 (en) * 2009-07-17 2011-01-20 Carnegie Institute Of Washington A mechanism and method for regulating glycogen synthase kinase 3 (gsk3)-related kinases
CN103037690B (zh) * 2010-03-24 2016-04-27 俄亥俄州立大学 用于葡萄糖转运抑制的组合物和方法
DK3054996T3 (da) 2013-10-07 2023-07-10 Igl Pharma Inc Fremgangsmåde til fremstilling af terapeutiske knoglemidler af høj renhed
US9580699B2 (en) 2014-04-17 2017-02-28 University of Pittsburgh—of the Commonwealth System of Higher Education TRPV1 modulatory gene product that affects TRPV1-specific pain behavioral responses identified in a functional screen of an HSV-based cDNA library
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
CN107530376A (zh) 2015-02-18 2018-01-02 恩立夫克治疗有限责任公司 用于癌症治疗的联合免疫疗法和细胞因子控制疗法
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
IL287500B2 (en) 2015-04-21 2023-12-01 Enlivex Therapeutics Rdo Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
CA3014885A1 (en) 2016-02-18 2017-08-24 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
US11377643B2 (en) 2017-05-31 2022-07-05 Ultragenyx Pharmaceutical Inc. Therapeutics for glycogen storage disease type III
CN110051841B (zh) * 2019-05-28 2021-02-02 北京大学 Nat10抑制剂在制备用于抑制hif表达的药物中的应用
EP4323951A1 (en) * 2021-04-14 2024-02-21 Ventana Medical Systems, Inc. Transformation of histochemically stained images into synthetic immunohistochemistry (ihc) images
CN118924748A (zh) * 2024-07-19 2024-11-12 广州百吉生物制药有限公司 一种诱导实体肿瘤分化的药物及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001005954A1 (en) * 1999-07-19 2001-01-25 Isis Pharmaceuticals, Inc. Antisense modulation of liver glycogen phosphorylase expression
WO2001052862A1 (en) * 2000-01-19 2001-07-26 Isis Pharmaceuticals, Inc. Antisense modulation of glycogen synthase kinase 3 beta expression
WO2001085685A1 (en) * 2000-05-11 2001-11-15 Consejo Superior Investigaciones Cientificas Heterocyclic inhibitors of glycogen synthase kinase gsk-3
JP2002128673A (ja) * 2000-07-31 2002-05-09 Pfizer Prod Inc 哺乳動物における腫瘍の増殖を阻害する方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08198758A (ja) * 1995-01-24 1996-08-06 Aomori Pref Gov グリコーゲンの癌予防剤としての用法
US5939284A (en) * 1996-12-05 1999-08-17 Smithkline Beecham Corporation Protein phosphatase 1 binding protein, R5
US20030166592A1 (en) * 1999-07-19 2003-09-04 Monia Brett P. Antisense modulation of liver glycogen phosphorylase expression
DE60137829D1 (de) * 2000-01-13 2009-04-16 Genentech Inc Menschliche stra6 polypeptide
US20040180845A1 (en) * 2003-03-13 2004-09-16 Newgard Christopher B. Methods and compositions for modulating glycogen synthesis and breakdown

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001005954A1 (en) * 1999-07-19 2001-01-25 Isis Pharmaceuticals, Inc. Antisense modulation of liver glycogen phosphorylase expression
WO2001052862A1 (en) * 2000-01-19 2001-07-26 Isis Pharmaceuticals, Inc. Antisense modulation of glycogen synthase kinase 3 beta expression
WO2001085685A1 (en) * 2000-05-11 2001-11-15 Consejo Superior Investigaciones Cientificas Heterocyclic inhibitors of glycogen synthase kinase gsk-3
JP2002128673A (ja) * 2000-07-31 2002-05-09 Pfizer Prod Inc 哺乳動物における腫瘍の増殖を阻害する方法

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013504039A (ja) * 2009-09-02 2013-02-04 ナショナル・チン・フア・ユニバーシティ 致死性細胞を検出する方法および組成物ならびにその使用
JP2015534946A (ja) * 2012-10-12 2015-12-07 ビジョン グローバル ホールディングス リミテッドＶｉｓｉｏｎ Ｇｌｏｂａｌ Ｈｏｌｄｉｎｇｓ Ｌｔｄ． がんの標的治療およびがんの再発予防のためのヘモグロビンベース系酸素運搬体含有医薬組成物
JP2013135674A (ja) * 2013-01-11 2013-07-11 Tohoku Univ 運動に応答して筋肉細胞において発現変動するタンパク質及びそれらの受容体、それらをコードする遺伝子、並びにそれらを用いたスクリーニング方法

Also Published As

Publication number Publication date
AU2003282306A1 (en) 2004-05-25
US20090041740A1 (en) 2009-02-12
WO2004039412A3 (en) 2004-11-04
CA2503422A1 (en) 2004-05-13
CN1741821A (zh) 2006-03-01
EP1556088A2 (en) 2005-07-27
CN1741821B (zh) 2011-08-10
WO2004039412A2 (en) 2004-05-13
US20050202559A1 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
JP2006508939A5 (OSRAM)
US20090041740A1 (en) Cancer treatment by metabolic modulations
Bond et al. The integrated stress response and phosphorylated eukaryotic initiation factor 2α in neurodegeneration
Lv et al. lncMGPF is a novel positive regulator of muscle growth and regeneration
Shen et al. Targeting the p53 signaling pathway in cancers: molecular mechanisms and clinical studies
JP4351896B2 (ja) ｐ３８／ＪＴＶ−１を有効成分とする癌治療用薬学的組成物及び癌治療用薬学的組成物のスクリーニング方法
US11446398B2 (en) Regulated biocircuit systems
Lin et al. p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression
Crone et al. ErbB2 is essential in the prevention of dilated cardiomyopathy
Holmes et al. The protein arginine methyltransferase PRMT5 confers therapeutic resistance to mTOR inhibition in glioblastoma
Roberts et al. GRP78/Dna K is a target for nexavar/stivarga/votrient in the treatment of human malignancies, viral infections and bacterial diseases
Yi et al. Targeting USP2 regulation of VPRBP-mediated degradation of p53 and PD-L1 for cancer therapy
BR112020018049A2 (pt) Composições de cartirina e métodos para uso
US20090304663A1 (en) Use of gsk-3 inhibitors for the treatment of prostate cancer
Birks et al. Targeting the GD3 acetylation pathway selectively induces apoptosis in glioblastoma
Zhang et al. Secreted PTEN binds PLXDC2 on macrophages to drive antitumor immunity and tumor suppression
Orthwein et al. Optimal functional levels of activation-induced deaminase specifically require the Hsp40 DnaJa1
Kumagai et al. Eradication of Myc-overexpressing small cell lung cancer cells transfected with herpes simplex virus thymidine kinase gene containing Myc-Max response elements
Lin et al. MiR‐183‐5p protects rat hearts against myocardial ischemia/reperfusion injury through targeting VDAC1
US20070135340A1 (en) IGF-1 novel peptides
WO2024104433A9 (zh) 半乳糖凝集素-1作为免疫检查点在制备肿瘤免疫治疗药物中的应用以及该药物
Ayimugu et al. Investigation of the involvement of parkin in parkinson's disease and cancer by monitoring the changes in sh-sy5y cells at the nuclear proteome level
US7160859B2 (en) Mst1 modulation of apoptosis in cardiac tissue and modulators of Mst1 for treatment and prevention of cardiac disease
Uchiumi et al. Possible roles of a duplicated GGAA motif as a driver cis-element for cancer-associated genes
Gjerset et al. Sensitization of tumors to chemotherapy through gene therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061025

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20061113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100428

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110121

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110809